GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001081028 | Thyroid | HT | regulation of cell-substrate adhesion | 27/1272 | 221/18723 | 2.22e-03 | 1.90e-02 | 27 |
GO:001095026 | Thyroid | HT | positive regulation of endopeptidase activity | 23/1272 | 179/18723 | 2.39e-03 | 2.03e-02 | 23 |
GO:005109010 | Thyroid | HT | regulation of DNA-binding transcription factor activity | 46/1272 | 440/18723 | 2.39e-03 | 2.03e-02 | 46 |
GO:00319584 | Thyroid | HT | corticosteroid receptor signaling pathway | 5/1272 | 15/18723 | 2.43e-03 | 2.05e-02 | 5 |
GO:001077020 | Thyroid | HT | positive regulation of cell morphogenesis involved in differentiation | 13/1272 | 79/18723 | 2.44e-03 | 2.06e-02 | 13 |
GO:007137519 | Thyroid | HT | cellular response to peptide hormone stimulus | 33/1272 | 290/18723 | 2.53e-03 | 2.12e-02 | 33 |
GO:00486608 | Thyroid | HT | regulation of smooth muscle cell proliferation | 23/1272 | 180/18723 | 2.57e-03 | 2.15e-02 | 23 |
GO:00720019 | Thyroid | HT | renal system development | 34/1272 | 302/18723 | 2.62e-03 | 2.19e-02 | 34 |
GO:003298419 | Thyroid | HT | protein-containing complex disassembly | 27/1272 | 224/18723 | 2.69e-03 | 2.24e-02 | 27 |
GO:190320216 | Thyroid | HT | negative regulation of oxidative stress-induced cell death | 10/1272 | 53/18723 | 2.69e-03 | 2.24e-02 | 10 |
GO:00000457 | Thyroid | HT | autophagosome assembly | 15/1272 | 99/18723 | 2.73e-03 | 2.25e-02 | 15 |
GO:00609969 | Thyroid | HT | dendritic spine development | 15/1272 | 99/18723 | 2.73e-03 | 2.25e-02 | 15 |
GO:001943920 | Thyroid | HT | aromatic compound catabolic process | 48/1272 | 467/18723 | 2.74e-03 | 2.25e-02 | 48 |
GO:000716218 | Thyroid | HT | negative regulation of cell adhesion | 34/1272 | 303/18723 | 2.76e-03 | 2.27e-02 | 34 |
GO:006007019 | Thyroid | HT | canonical Wnt signaling pathway | 34/1272 | 303/18723 | 2.76e-03 | 2.27e-02 | 34 |
GO:00327573 | Thyroid | HT | positive regulation of interleukin-8 production | 11/1272 | 62/18723 | 2.80e-03 | 2.29e-02 | 11 |
GO:015011626 | Thyroid | HT | regulation of cell-substrate junction organization | 12/1272 | 71/18723 | 2.80e-03 | 2.29e-02 | 12 |
GO:004259319 | Thyroid | HT | glucose homeostasis | 30/1272 | 258/18723 | 2.80e-03 | 2.29e-02 | 30 |
GO:000283110 | Thyroid | HT | regulation of response to biotic stimulus | 36/1272 | 327/18723 | 2.91e-03 | 2.36e-02 | 36 |
GO:003350019 | Thyroid | HT | carbohydrate homeostasis | 30/1272 | 259/18723 | 2.97e-03 | 2.40e-02 | 30 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AR | SNV | Missense_Mutation | | c.2595N>A | p.Asp865Glu | p.D865E | P10275 | protein_coding | deleterious(0) | probably_damaging(0.923) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | | SD |
AR | SNV | Missense_Mutation | | c.1912N>A | p.Leu638Met | p.L638M | P10275 | protein_coding | tolerated(0.07) | benign(0.316) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
AR | SNV | Missense_Mutation | novel | c.1082N>A | p.Ser361Asn | p.S361N | P10275 | protein_coding | tolerated_low_confidence(0.27) | benign(0.015) | TCGA-AC-A8OP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | | c.1681N>A | p.Leu561Met | p.L561M | P10275 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-BH-A18L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | | c.1703C>T | p.Ser568Phe | p.S568F | P10275 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
AR | SNV | Missense_Mutation | novel | c.2642N>A | p.Leu881Gln | p.L881Q | P10275 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-OL-A66K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | novel | c.585N>T | p.Gln195His | p.Q195H | P10275 | protein_coding | tolerated_low_confidence(0.13) | benign(0.005) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AR | SNV | Missense_Mutation | novel | c.2718N>T | p.Lys906Asn | p.K906N | P10275 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AR | SNV | Missense_Mutation | novel | c.967N>A | p.Glu323Lys | p.E323K | P10275 | protein_coding | tolerated_low_confidence(0.11) | benign(0.265) | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
AR | SNV | Missense_Mutation | | c.2462G>T | p.Gly821Val | p.G821V | P10275 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | FLUOCINOLONE ACETONIDE | FLUOCINOLONE ACETONIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | 4-CHLOROMERCURIBENZOIC ACID | 4-CHLOROMERCURIBENZOIC ACID | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | agonist | CHEMBL2107067 | TESTOSTERONE UNDECANOATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | DIDECYLDIMETHYLAMMONIUM CHLORIDE | DIDECYLDIMETHYLAMMONIUM CHLORIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | QUININE SULFATE | QUININE SULFATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | NILUTAMIDE | NILUTAMIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | RALOXIFENE HYDROCHLORIDE | RALOXIFENE HYDROCHLORIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | ARN-509 | APALUTAMIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | CRUFOMATE | CRUFOMATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | 2-AMINOFLURENE | CHEMBL84472 | |